Èñòîðèÿ èíñòèòóòà
Íàöèîíàëüíûé èíñòèòóò ôòèçèàòðèè è
ïóëüìîíîëîãèè èì Ô.Ã. ßíîâñêîãî

Ïîñåòèòå íàøó ñòðàíèöóâ Facebook

 

Êëèíèêà
Êîíòàêòû

Ïåðåõîä íà òèòóëüíóþ ñòðàíèöóÏîèñê ïî ñàéòó

Óêðàèíñêèé ïóëüìîíîëîãè÷åñêèé æóðíàë

Îá èíñòèòóòå:

èñòîðèÿ,

îáùèå ïîëîæåíèÿ,

ñòðóêòóðà,

íàó÷íàÿ äåÿòåëüíîñòü,

ïëàíû ÍÈÐ,

ëå÷åáíî-äèàãíîñòè÷åñêàÿ ðàáîòà,

âåäóùèå ó÷åíûå

Íîâîñòè:

íîâèíêè íà ñàéòå

Íàøè èçäàíèÿ:

"Óêðàèíñêèé ïóëüìîíîëîãè÷åñêèé æóðíàë" (ÓÏÆ),
"Óêðàèíñêèé õèìèîòåðàïåâòè÷åñêèé æóðíàë" (ÓÕÆ),
"Àñòìà è àëëåðãèÿ" (ÀÀ)
"Èíôóçèÿ&
Õèìèîòåðàïèÿ" (ÈÕ)

Îðèãèíàëüíûå ñòàòüè:

îðèãèíàëüíûå íàó÷íûå ñòàòüè, ðàíåå íèãäå íå ïóáëèêîâàâøèåñÿ

Íîâîââåäåíèÿ:

ìåòîäè÷åñêèå ðåêîìåíäàöèè, èíôîðìàöèîííûå ïèñüìà,
âåäîìñòâåííûå èíñòðóêöèè,
íîâîââåäåíèÿ, ìîíîãðàôèè

Ïàòåíòû:

ïàòåíòû è àâòîðñêèå ñâèäåòåëüñòâà èíñòèòóòà

Îò÷åòû î ÍÈÐ:

ðåôåðàòû çàêîí÷åííûõ íàó÷íî-èññëåäîâàòåëüñêèõ ðàáîò

Ïîäãîòîâêà êàäðîâ:

àñïèðàíòóðà,

êëèíè÷åñêàÿ îðäèíàòóðà,
êóðñû èíôîðìàöèè è ñòàæèðîâêè,

â ïîìîùü àñïèðàíòó è ñîèñêàòåëþ

Íàó÷íûå ôîðóìû:

ðåçîëþöèè è îáðàùåíèÿ ñúåçäîâ, êîíôåðåíöèé, ñîâåùàíèé...

Èíôîðìàöèÿ äëÿ ñïåöèàëèñòîâ:

îáçîðû ëèòåðàòóðû, ñòàòèñòè÷åñêàÿ èíôîðìàöèÿ, íîâîå â ëå÷åíèè òóáåðêóëåçà è íåñïåöèôè÷åñêèõ çàáîëåâàíèé ëåãêèõ...

Èíôîðìàöèÿ äëÿ íàñåëåíèÿ:

ïîëåçíàÿ èíôîðìàöèÿ î çàáîëåâàíèÿõ ëåãêèõ, èõ ïðîôèëàêòèêå è ëå÷åíèè

2011. - ¹ 2.
Ç̲ÑÒ / ÑÎÄÅÐÆÀÍÈÅ / CONTENTS

ÌÀÒÅвÀËÈ ÍÀÓÊÎÂÎ-ÏÐÀÊÒÈ×Íί ÊÎÍÔÅÐÅÍÖ²¯ / PROCEEDINGS OF THE CONFERENCE

 

Þ. È. Ôåùåíêî
ÕÐÎÍÈ×ÅÑÊÎÅ ÎÁÑÒÐÓÊÒÈÂÍÎÅ ÇÀÁÎËÅÂÀÍÈÅ ËÅÃÊÈÕ — ÀÊÒÓÀËÜÍÀß ÌÅÄÈÊÎ-ÑÎÖÈÀËÜÍÀß ÏÐÎÁËÅÌ

®

Yu. I. Feshchenko
CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A MEDICAL AND SOCIAL CHALLENGE

 

 

Ë. À. ßøèíà
ÁÀÇÈÑÍÀß ÒÅÐÀÏÈß ÁÎËÜÍÛÕ ÕÎÇË

®

L. A. Yashina
MAINTENANCE THERAPY OF PATIENTS WITH COPD

 

À. ß. Äçþáëèê
ÎÁÎÑÒÐÅÍÈÅ ÕÎÇË: ÑÎÂÐÅÌÅÍÍÛÅ ÏÐÈÍÖÈÏÛ ËÅ×ÅÍÈß

®

A. Ya. Dziublyk
EXACERBATION OF COPD: MODERN MANAGEMENT PRINCIPLES

 

Â. Ê. Ãàâðèñþê
ÏÐÈÍÖÈÏÛ ÒÅÐÀÏÈÈ ÁÎËÜÍÛÕ Ñ ÎÑËÎÆÍÅÍÈßÌÈ ÕÎÇË

®

V. K. Gavrysiuk
PRINCIPLES OF MANAGEMENT OF PATIENTS WITH COPD COMPLICATIONS

 

Ò. À. Ïåðöåâà
ÐÅÇÓËÜÒÀÒÛ ÈÑÑËÅÄÎÂÀÍÈß UPLIFT®. ÑÓÁÀÍÀËÈÇ ÐÅÇÓËÜÒÀÒÎÂ Ó ÁÎËÜÍÛÕ ÕÎÇË, ÊÎÒÎÐÛÅ ÐÀÍÅÅ ÍÅ ËÅ×ÈËÈÑÜ

®

T. A. Pertseva
UPLIFT® STUDY RESULTS: SUB-ANALYSIS IN SUBGROUP OF PREVIOUSLY UNTREATED PATIENTS

 

Ë. À. ßøèíà
ÐÅÇÓËÜÒÀÒÛ ÈÑÑËÅÄÎÂÀÍÈß POET È ÈÕ ÊËÈÍÈ×ÅÑÊÎÅ ÇÍÀ×ÅÍÈÅ Â ÏÐÀÊÒÈÊÅ ÂÐÀ×À

®

L. A. Yashina
POET STUDY RESULTS AND ITS CLINICAL SIGNIFICANCE IN MEDICAL PRACTICE

 

Ì. Ì. Îñòðîâñüêèé
ÁÐÎÍÕÎÎÁÑÒÐÓÊÒÈÂÍÈÉ ÑÈÍÄÐÎÌ: ÀÊÒÓÀËÜͲ ÏÈÒÀÍÍß Ä²ÀÃÍÎÑÒÈÊÈ ÒÀ ˲ÊÓÂÀÍÍß

®

M. M. Ostrovskyi
BRONCHIAL OBSTRUCTIVE SYNDROME: DIAGNOSIS AND MANAGEMENT

 

Ì. À. Ïîëÿíñêàÿ
ÎÖÅÍÊÀ ÝÔÔÅÊÒÈÂÍÎÑÒÈ ÍÅÁÓËÀÉÇÅÐÍÎÉ ÒÅÐÀÏÈÈ ÁÅÐÎÄÓÀËÎÌ

®

M. A. Polianska
EVALUATION OF EFFECTIVENESS OF NEBULIZER THERAPY USING BERODUAL

 

Ò. À. Ïåðöåâà, Å. Â. Ìèðîíåíêî
ÕÐÎÍÈ×ÅÑÊÎÅ ÎÁÑÒÐÓÊÒÈÂÍÎÅ ÇÀÁÎËÅÂÀÍÈÅ ËÅÃÊÈÕ: ÐÎËÜ ÏÐÎÒÈÂÎÂÎÑÏÀËÈÒÅËÜÍÎÉ ÒÅÐÀÏÈÈ

®

T. A. Pertseva, E. V. Mironchenko
CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE ROLE OF ANTI-INFLAMMATORY THERAPY

 

Þ. Ì. Ìîñòîâîé, À. Â. Äåì÷óê
ÂÛÁÎÐ ÀÍÒÈÁÀÊÒÅÐÈÀËÜÍÎÃÎ ÏÐÅÏÀÐÀÒÀ ÏÐÈ ÎÁÎÑÒÐÅÍÈÈ ÕÎÇË Â ÀÌÁÓËÀÒÎÐÍÛÕ ÓÑËÎÂÈßÕ ÍÀ ÎÑÍÎÂÀÍÈÈ ÔÀÐÌÀÊÎÝÊÎÍÎÌÈ×ÅÑÊÎÃÎ ÀÍÀËÈÇÀ

®

Yu. M. Mostovoy, A. V. Demchuk
THE CHOICE OF ANTIBIOTIC MEDICATION IN EXACERBATION OF COPD IN OUT-PATIENT SETTING BASED ON PHARMACOECONOMIC ANALYSIS

 

Ë. È. Êîíîïêèíà, Ò. À. Ïåðöåâà
ÍÎÂÛÅ ÀÑÏÅÊÒÛ Â ËÅ×ÅÍÈÈ ÁÎËÜÍÛÕ ÕÐÎÍÈ×ÅÑÊÈÌ ÎÁÑÒÐÓÊÒÈÂÍÛÌ ÇÀÁÎËÅÂÀÍÈÅÌ ËÅÃÊÈÕ

®

L. I. Konopkina, T. A. Pertseva
NOVEL ASPECTS IN TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

 

Ò. À. Ïåðöåâà
ÝÏÈÄÅÌÈÎËÎÃÈß È ÄÈÀÃÍÎÑÒÈÊÀ ÕÐÎÍÈ×ÅÑÊÎÃÎ ÎÁÑÒÐÓÊÒÈÂÍÎÃÎ ÇÀÁÎËÅÂÀÍÈß ËÅÃÊÈÕ

®

T. A. Pertseva
EPIDEMIOLOGY AND DIAGNOSING OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

 

Ë. À. ßøèíà
ÎÁÎÑÍÎÂÀÍÈÅ ÖÅËÅÑÎÎÁÐÀÇÍÎÑÒÈ È ÀÍÀËÈÇ ÝÔÔÅÊÒÈÂÍÎÑÒÈ ÊÎÌÁÈÍÈÐÎÂÀÍÍÎÉ ÒÅÐÀÏÈÈ ÕÎÇË

®

L. A. Yashina
JUSTIFICATION OF USE AND EVALUATION OF EFFICACY OF COMBINATION THERAPY IN COPD

 

Þ. Ì. Ìîñòîâîé, À. Â. Äåì÷óê
ÕÎÇË. ÑÈÑÒÅÌÍÛÅ ÝÔÔÅÊÒÛ È ÈÕ ÏÐÎÔÈËÀÊÒÈÊÀ

®

Yu. M. Mostovoy, A. V. Demchuk
COPD: SYSTEMIC EFFECTS AND THEIR PROPHYLAXIS

 

Ë. À. ßøèíà
ÊÎÍÒÐÎËÜ ÍÀÄ ÂÎÑÏÀËÈÒÅËÜÍÛÌ ÏÐÎÖÅÑÑÎÌ ÏÐÈ ÕÎÇË

®

L. A. Yashina
INFLAMMATION CONTROL IN COPD

 

À. ß. Äçþáëèê
ÍÎÂÛÅ ÂÎÇÌÎÆÍÎÑÒÈ Â ÒÅÐÀÏÈÈ ÁÎËÜÍÛÕ ÕÎÇË

®

A. Ya. Dziublyk
NEW OPPORTUNITIES IN MANAGEMENT OF COPD PATIENTS

 

Ò. À. Ïåðöåâà
ÏÐÎÒÈÂÎÂÎÑÏÀËÈÒÅËÜÍÀß ÒÅÐÀÏÈß ÁÎËÜÍÛÕ ÕÎÇË: ÐÅÇÓËÜÒÀÒÛ ÊËÈÍÈ×ÅÑÊÈÕ ÈÑÑËÅÄÎÂÀÍÈÉ

®

T. A. Pertseva
ANTI-INFLAMMATORY THERAPY IN COPD PATIENTS: CLINICAL TRIAL RESULTS

 

Ñ. Ñ. Ñèìîíîâ
ÀÍÒÈÁÈÎÒÈÊÎÒÅÐÀÏÈß ÈÍÔÅÊÖÈÎÍÍÛÕ ÎÁÎÑÒÐÅÍÈÉ ÕÐÎÍÈ×ÅÑÊÎÃÎ ÁÐÎÍÕÈÒÀ

®

S. S. Simonov
ANTIBIOTIC THERAPY OF INFECTIOUS EXACERBATIONS OF CHRONIC BRONCHITIS

 

Í. Å. Ìîíîãàðîâà, Ò. Â. Çàêîìîëäèíà, À. Ñ. Ïàí÷èøêî, Å. Å. Ìîíîãàðîâà, À. Â. Ñåìåíäÿåâà
ÒÅÐÀÏÈß ÏÀÖÈÅÍÒÎÂ Ñ ÕÎÇË: ÂÎÇÌÎÆÍÎ ËÈ ÏÎÂËÈßÒÜ ÍÀ ÏÐÎÃÍÎÇ?

®

N. E. Monogarova, T. V. Zakomoldina, A. S. Panchishko, E. E. Monogarova, A. V. Semendiayeva
THERAPY OF COPD PATIENTS: IS IT POSSIBLE TO INFLUENCE A PROGNOSIS?

 

Ò. À. Ïåðöåâà, Â. Â. Äìèòðè÷åíêî
ÌÀÊÐÎËÈÄÛ: ÀÍÒÈÁÀÊÒÅÐÈÀËÜÍÛÅ ÝÔÔÅÊÒÛ È ÍÅ ÒÎËÜÊÎ

®

T. A. Pertseva, V. V. Dmitrichenko
MACROLIDES: ANTIBACTERIAL AND NON-ANTIBACTERIAL EFFECTS

 

 

Ñ. È. Ëåùåíêî
ÍÅÁÓËÀÉÇÅÐÍÀß ÒÅÐÀÏÈß — ÑÎÂÐÅÌÅÍÍÛÉ ÌÅÒÎÄ ËÅ×ÅÍÈß ÁÎËÜÍÛÕ ÕÎÇË

®

S. I. Leshchenko
NEBULIZER THERAPY — MODERN METHOD OF TREATMENT OF COPD PATIENTS
 

Ñ. Ñ. Ñèìîíîâ
ÀÍÒÈÁÈÎÒÈÊÎÒÅÐÀÏÈß ÈÍÔÅÊÖÈÉ ÍÈÆÍÈÕ ÄÛÕÀÒÅËÜÍÛÕ ÏÓÒÅÉ: Â ÔÎÊÓÑÅ ÌÀÊÐÎËÈÄÛ

®

S.S. Simonov
ANTIBIOTIC THERAPY OF LOWER RESPIRATORY TRACT INFECTIONS: A FOCUS ON MACROLIDES

 

 

ÎÐÈòÍÀËÜͲ ÑÒÀÒÒ² / ÎRIGINALS

 

Ñ. À. ×åðåíüêî, Ñ. Ë. Ìàòâååâà
ÊÎÐÐÅËßÖÈÈ ÌÅÆÄÓ ÊËÈÍÈ×ÅÑÊÈÌ ÒÅ×ÅÍÈÅÌ ÒÓÁÅÐÊÓËÅÇÀ ËÅÃÊÈÕ, ÔÓÍÊÖÈÅÉ ÙÈÒÎÂÈÄÍÎÉ ÆÅËÅÇÛ È ÍÅÊÎÒÎÐÛÌÈ ÖÈÒÎÊÈÍÀÌÈ

®

S. O. Cherenco, S. L. Matvyeyeva
CORRELATION BETWEEN CLINICAL COURSE OF PULMONARY TUBERCULOSIS, THYROID GLAND FUNCTION AND SOME CYTOKINES

 

Þ. Í. Ñèðåíêî, Ê. Â. Ìèõååâà
ÂÇÀÈÌÎÑÂßÇÜ ÏÎÊÀÇÀÒÅËÅÉ ÀÐÒÅÐÈÀËÜÍÎÃÎ ÄÀÂËÅÍÈß È ÏÎÊÀÇÀÒÅËÅÉ ÍÀÐÓØÅÍÈß ÄÛÕÀÍÈß ÂÎ ÂÐÅÌß ÑÍÀ Ó ÏÀÖÈÅÍÒÎÂ Ñ ÑÈÍÄÐÎÌÎÌ ÎÁÑÒÐÓÊÒÈÂÍÎÃÎ ÀÏÍÎÝ-ÃÈÏÎÏÍÎÝ ÑÍÀ È ÏÐÈ ÅÃÎ ÑÎ×ÅÒÀÍÈÈ Ñ ÕÎÇË

®

Yu. N. Sirenko, K. V. Miheeva
CORRELATION OF BLOOD PRESSURE INDICES AND SLEEP DISTURBANCE BREATHING INDICES IN PATIENTS WITH SLEEP APNEA AND ITS COMBINATION WITH COPD

 

 

À. Â. Ëèòâèíåíêî, Â. Â. Êóö
ÑÎÑÒÎßÍÈÅ ÖÅÍÒÐÀËÜÍÎÉ ÈÍÑÏÈÐÀÒÎÐÍÎÉ ÀÊÒÈÂÍÎÑÒÈ Ó ÁÎËÜÍÛÕ Ñ ÃÈÏÎÊÀÏÍÈÅÉ ÊÐÎÂÈ

®

A. V. Lytvynenko, V. V. Kuts
CENTRAL INSPIRATORY ACTIVITY IN PATIENTS WITH HYPOCAPNIA

 

Ï. Ô. Äóäêà, Ä. Â. Äîáðÿíñüêèé, Í. Ã. Áè÷êîâà, Î. ². Áîäàðåöüêà
ÑÒÀÍ ÃÅÌÎÐÅÎËÎò×Íί ² ²ÌÓÍÍί ÑÈÑÒÅÌÈ ÒÀ ÅÔÅÊÒÈÂͲÑÒÜ ÔÅÍÑϲÐÈÄÓ Ó ÕÂÎÐÈÕ ÍÀ ÕÐÎͲ×ÍÅ ÎÁÑÒÐÓÊÒÈÂÍÅ ÇÀÕÂÎÐÞÂÀÍÍß ËÅÃÅÍÜ ² ÒÀ ²² ÑÒÀIJ¯

®

P. F. Dudka, D. V. Dobryanskiy, N. G. Bichkova, O. I. Bodareckay
STATE OF BLOOD RHEOLOGY AND IMMUNE SYSTEM AND EFFICIENCY OF FENSPIRID IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ² AND ²² STAGES

 

Ì. Ï. ʳðñàíîâà, Ì. ². Òîâò-Êîðøèíñüêà, Ò. Ñ. Áðþçã³íà
ÎÖ²ÍÊÀ ÆÈÐÍÎÊÈÑËÎÒÍÎÃÎ ÑÏÅÊÒÐÓ Ë²Ï²Ä²Â ÑÈÐÎÂÀÒÊÈ ÊÐβ ÒÀ ÌÅÌÁÐÀÍ ÅÐÈÒÐÎÖÈÒ²Â Ó ÕÂÎÐÈÕ ÍÀ ÕÐÎͲ×ÍÅ ÎÁÑÒÐÓÊÒÈÂÍÅ ÇÀÕÂÎÐÞÂÀÍÍß ËÅÃÅÍÜ Ó ÏΪÄÍÀÍͲ Ç ÀÐÒÅвÀËÜÍÎÞ Ã²ÏÅÐÒÅÍDzªÞ

®

M. P. Kirsanova, M. I. Tovt-Korshynska, T. S. Brjuzgina
FATTY-ACID SPECTRUM OF LIPID SERUM AND ÅRYTHROCYTES MEMBRANES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ASSOCIATION WITH ARTERIAL HYPERTENSION

 

ÎÃËßÄÈ Ë²ÒÅÐÀÒÓÐÈ / REVIEWS

 

Ó. Á. ×óëîâñüêà, Î. Ñ. Òîëîõ
ÏÐÀÂÈËÜͲ вØÅÍÍß Ó ÇÀÑÒÎÑÓÂÀÍͲ ÀÍÒÈÁÀÊÒÅвÀËÜÍί ÒÅÐÀϲ¯ ÇÀÃÎÑÒÐÅÍÜ ÕÐÎͲ×ÍÎÃÎ ÎÁÑÒÐÓÊÒÈÂÍÎÃÎ ÇÀÕÂÎÐÞÂÀÍÍß ËÅÃÅÍÜ

®

U. B. Chulovska, O. S. Tolokh
CORRECT DECISIONS IN APPLICATION OF ANTIBACTERIAL THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION

 

²ÍÔÎÐÌÀÖ²ß / INFORMATION

 

ÝÔÔÅÊÒÈÂÍÎÑÒÜ ÌÎÍÒÅËÓÊÀÑÒÀ Ó ÁÎËÜÍÛÕ ÁÐÎÍÕÈÀËÜÍÎÉ ÀÑÒÌÎÉ Ñ ÑÎÏÓÒÑÒÂÓÞÙÈÌÈ ÇÀÁÎËÅÂÀÍÈßÌÈ ÏÎËÎÑÒÈ ÍÎÑÀ È ÎÊÎËÎÍÎÑÎÂÛÕ ÏÀÇÓÕ

®

EFFICACY OF MONTELUKAST IN PATIENTS WITH ASTHMA AND CONCOMITANT DISEASES OF NASAL CAVITY AND PARANASAL SINUSES

 

 

ÏÐÎÔÅÑÎÐÓ ÎËÅÊÑÀÍÄÐÓ ßÐÎÑËÀÂÎÂÈ×Ó ÄÇÞÁËÈÊÓ — 60 ÐÎʲÂ

®

PROFESSOR’S ALEXANDR DZIUBLYK 60TH ANNIVERSARY

 

ÑÎËÄÀÒ×ÅÍÊÎ ÑÅÐÃÅÉ ÑÅÐÃÅÅÂÈ× (Ê 60-ËÅÒÈÞ ÑÎ ÄÍß ÐÎÆÄÅÍÈß)

®

PROFESSOR’S SERGEY SOLDATCHENKO 60TH ANNIVERSARY

 

ÑÒÀÍÄÀÐÒÈ Ä²ÀÃÍÎÑÒÈÊÈ ÒÀ ˲ÊÓÂÀÍÍß / STANDARDS OF DIAGNOSTICS AND TREATMENT

 

ÎÔÈÖÈÀËÜÍÎÅ ÏÎËÎÆÅÍÈÅ ÀÒÎ/ÅÐÎ/ßÐÎ/ÀËÀÒ: ÈÄÈÎÏÀÒÈ×ÅÑÊÈÉ ËÅÃÎ×ÍÛÉ ÔÈÁÐÎÇ: ÄÎÊÀÇÀÒÅËÜÍÎ-ÎÑÍÎÂÀÍÍÎÅ ÐÓÊÎÂÎÄÑÒÂÎ ÏÎ ÄÈÀÃÍÎÑÒÈÊÅ È ÂÅÄÅÍÈÞ

®

AN OFFICIAL ATS/ERS/JRS/ALAT STATEMENT: IDIOPATHIC PULMONARY FIBROSIS: EVIDENCE-BASED GUIDELINES FOR DIAGNOSIS AND MANAGEMENT

 

 

 



HomeÏîèñê Ïðî èíñòèòóòÍîâîñòè Íàøè èçäàíèÿ Îðèãèíàëüíûå ñòàòòüè Íîâîââåäåíèÿ
ÏàòåíòûÎò÷åòû î ÍÄÐ Ïîäãîòîâêà êàäðîâ Íàó÷íûå ôîðóìû
Èíôîðìàöèÿ äëÿ ñïåöèàëèñòîâÈíôîðìàöèÿ äëÿ íàñåëåíèÿÌåäèöèíñêèå óñëóãè


© Îòäåë ÈÊÒ
ÍÈÔÏ

Îòïðàâèòü E-mail â Èíñòèòóò

www.ifp.kiev.ua